First-in-Human Single Ascending and Multiple Dose of GLPG0555

NCT01023321 · clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
35
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Lakefront Biotherapeutics NV